EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Timing of Cardiac Contractility Modulation Therapy Implementation

Goekhan Yuecel iD, Gamze Yildirim, Kristin Schreiner, Svetlana Hetjens, Konstantinos Giannakopoulos, Abbass Kodeih, Mostafa Khalil, Babak Yazdani iD, Faeq Husain-Syed iD, Daniel Duerschmied iD, William T Abraham, Ibrahim Akin iD und 1 weitere

Clinical Cardiology · 2026-11 · 49 (11)

DOI: 10.1002/clc.70507 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Cardiology, online erschienen am 31.10.2026. Verfasst von Goekhan Yuecel und 12 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Medicine, University Medical Centre Mannheim, Medical Faculty Mannheim of the University of Heidelberg, Mannheim, Germany. Hauptthemen laut MEDLINE: Heart Failure, Myocardial Contraction, Ventricular Function, Left, Stroke Volume. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Symptomatic chronic heart failure (HF) despite medical treatment can be addressed with cardiac contractility modulation (CCM) therapy, which has yet to have been investigated regarding outcome differences between early versus late implementation. Methods and Results CCM recipients from the Mannheim Cardiac Contractility Modulation Observational Registry (MAINTAINED) aged ≤ 70 years at implantation were grouped with regard to implantation time after the first diagnosis of CCM indicating HF (New York Heart Association classification (NYHA) ≥ 2 and left ventricular ejection fraction (LVEF) = 25%–45%) into either Early‐ (EC, n = 50, implantation < 13 months after diagnosis) or Late‐Implantation Group (LC, n = 81, implantation ≥ 13 months after diagnosis). Both groups were compared regarding survival, NYHA, LVEF, and HF‐related hospitalizations for up to 60 months. The mean implantation time after the first diagnosis were 5.85 ± 3.1 versus 92 ± 70.2 months (first values EC, p < 0.05). Mean survival was better for EC (55.2 ± 1.7 vs. 52.8 ± 1.6 months, p < 0.05). Improvements in NYHA (2.98 ± 0.47 to 2.0 ± 0.73 vs. 3.01 ± 0.46 to 2.25 ± 0.8, both p < 0.05) and LVEF (23.2 ± 7.5 to ± 38.82 ± 12.85 vs. 23.9 ± 7 to 29.92 ± 8.9%, each p < 0.05) were comparable, with differences in terms of grouping. Hospitalizations due to HF were more frequent to LC patients (39 vs. 110 events, Odds Ratio 2.1).

Conclusions

Heart failure patients might experience improvements in functional status and left ventricular reverse remodeling following CCM therapy, regardless of the timing of implantation. Early implementation of CCM within the first year of CCM suitable HF might provide additional benefits regarding survival, left ventricular systolic recovery and protection against heart failure hospitalizations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureMyocardial ContractionVentricular Function, LeftStroke VolumeHumansFemaleTime FactorsMaleTreatment OutcomeAgedRegistriesMiddle AgedRecovery of FunctionChronic DiseaseFollow-Up Studies

Stichwörter der Autor:innen

CIEDcardiac contractility modulationheart failuretreatment timing

Autor:innen und Institutionen

  • First Department of Medicine, University Medical Centre Mannheim, Medical Faculty Mannheim of the University of Heidelberg, Mannheim, Germany.
  • German Centre for Cardiovascular Research, Partner Site Heidelberg-Mannheim, Mannheim, Germany.
  • Department of Medical Statistics and Biomathematics, University Medical Centre Mannheim, Medical Faculty Mannheim of the Heidelberg University, Mannheim, Germany.
  • First Department of Cardiology, Hippokration General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • Fifth Department of Medicine, University Medical Centre Mannheim, Medical Faculty Mannheim of the Heidelberg University, Mannheim, Germany.
  • Department of Internal Medicine II, Division of Nephrology, University Hospital Giessen and Marburg, Justus-Liebig-University Giessen, Giessen, Germany.

ORCID-Profile: Goekhan Yuecel, Babak Yazdani, Faeq Husain-Syed, Daniel Duerschmied, Ibrahim Akin

Zitieren

APA

Yuecel, G., Yildirim, G., Schreiner, K., Hetjens, S., Giannakopoulos, K., Kodeih, A., Khalil, M., Yazdani, B., Husain-Syed, F., Duerschmied, D., Abraham, W. T., Akin, I., & Kuschyk, J. (2026). Timing of Cardiac Contractility Modulation Therapy Implementation. Clinical Cardiology, 49(11). https://doi.org/10.1002/clc.70507

Vancouver

Yuecel G, Yildirim G, Schreiner K, Hetjens S, Giannakopoulos K, Kodeih A, et al. Timing of Cardiac Contractility Modulation Therapy Implementation. Clinical Cardiology. 2026;49(11). doi:10.1002/clc.70507

BibTeX
@article{Yuecel2026,
  author = {Yuecel, Goekhan and Yildirim, Gamze and Schreiner, Kristin and Hetjens, Svetlana and Giannakopoulos, Konstantinos and Kodeih, Abbass and Khalil, Mostafa and Yazdani, Babak and Husain-Syed, Faeq and Duerschmied, Daniel and Abraham, William T and Akin, Ibrahim and Kuschyk, Jürgen},
  title = {Timing of Cardiac Contractility Modulation Therapy Implementation},
  journal = {Clinical Cardiology},
  year = {2026},
  volume = {49},
  number = {11},
  doi = {10.1002/clc.70507}
}
Kostenlos starten →